Moss, 27 October 2022

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the third quarter of 2022.

Highlights
o Sales revenue of MNOK 23.1 in 3Q22, an increase of 34% (35% organic growth) vs
3Q21
o Strong growth in the US enabled by recent distribution agreement
o Additional US distribution agreement for Cystatin C announced in August 2022
is expected to support revenue growth from 2023
o IVDR certification achieved, demonstrating Gentian's commitment to deliver
safe and effective products
o Good progress made on NT-proBNP, a working prototype has been developed from
the new immunoparticle candidate 
o GCAL® is well received in the market and Siemens collaboration is developing
positively


"The Gentian team delivered on several important milestones in the third
quarter. Importantly, we achieved IVDR approval, while good progress was made
for our two potential blockbuster products GCAL and NT-proBNP. For GCAL, we see
broadening market interest in the product and sales are ticking up. This is a
result of clinical studies proving the products' value proposition, endorsements
from key opinion leaders and successful marketing and sales efforts together
with our commercial partners. Our established products continue to win market
share, resulting in strong revenue growth. The common demand driver is a growing
and aging population which increases the need for diagnostic tests in
combination with a need for increased diagnostic efficiency which is a key
advantage for Gentian's immonuassays," commented Hilja Ibert, CEO of Gentian
Diagnostics.

NT-proBNP, the cardiac marker currently in product development, progressed
positively. Initial results with the lead candidate proved to be reproducible,
and as a result a working prototype has been established. Further, the
establishment of the reference method at the first trial site has been
accomplished as planned.

Additionally, one pipeline project was moved from the exploration phase to
proof-of-concept, while the other project in proof-of-concept progressed well.

"Going forward, we will continue to mature our pipeline projects while expanding
the market for the products already launched in line with our strategy for
long-term growth, "adds Ibert.


Webcast
Gentian's CEO Hilja Ibert and CFO Njaal Kind will present the results today at
10.00 am, followed by a Q&A session. Join the webcast and submit questions via
the following link:

https://attendee.gotowebinar.com/register/3718726872559445004


The webcast will be made available on the company's IR website after the
presentation.


IR contact:

Njaal Kind, CFO and COO
njaal.kind@gentian.no 
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Njaal Kind, CFO at Gentian
Diagnostics ASA, on 27 October 2022 at 08:00 CET.


About Gentian
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global human and veterinary diagnostics markets
through sales and representative offices in Sweden, USA and China. For more
information, please visit www.gentian.com.